Researchers had been working to develop vaccines for other coronaviruses, including the one that causes Middle East Respiratory System (MERS). They were able to adapt the system they’d been working on produce a candidate MERS vaccine to rapidly produce an experimental vaccine using the SARS-CoV-2 spike protein, according to the NIH Research Matters blog 애플워치 esim 다운로드.
The team, which includes scientists from the University of Pittsburgh, developed a method for delivering their MERS vaccine into mice using a microneedle patch midi 파일 다운로드.
These patches look like a very small piece of velcro, but they contain hundreds of microneedles composed of sugar. The needles would prick the skin and dissolve, releasing the vaccine new hymn mp3.
The NIH notes that the immune system is highly active in the skin, so delivering vaccines this way could produce a more rapid and robust immune response than standard injections under the skin 퓨전 360 다운로드.
When delivered by microneedle patch to mice, three different experimental MERS vaccines induced the production of antibodies against the virus 랩뷰 비전 다운로드. Antibody levels continued to increase over time in mice vaccinated by microneedle patch — up to 55 weeks, when the experiments ended.
Using knowledge gained from development of the MERS vaccine, the team made a similar microneedle vaccine targeting the spike protein of SARS-CoV-2 Mitos. The vaccine prompted robust antibody production in the mice within two weeks.
The study, which was funded by the National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and National Cancer Institute (NCI), appeared online on April 1, 2020, in EBioMedicine, a Lancet journal.
However, researchers cautioned that the vaccinated animals have not been tracked for long enough to determine if the long-term immune response is equivalent to what was observed with the MERS vaccine. Nor have the mice been challenged with SARS-CoV-2 infection.
The components of the experimental vaccine could be made quickly and at large scale, according to the researchers, and the final product doesn’t require refrigeration — so it could be produced and put in storage until needed.
The team now wants to obtain approval from the U.S. Food and Drug Administration to launch a phase 1 trial within the next several months.
Still, much work needs to be done by scientists to explore the safety and efficacy of this candidate vaccine. “Testing in patients would typically require at least a year and probably longer,” said Dr. Louis Falo Jr. of the University of Pittsburgh in a statement to the NIH blog. “This particular situation is different from anything we’ve ever seen, so we don’t know how long the clinical development process will take.”
Scientists — including NIH Director Dr. Anthony Fauci — have said that developing an effective vaccine for COVID-19 would take about 12 to 18 months.